Prof. Hong Yang 杨宏
Chief Physician, Professor
Department of Urology, Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, surgery, and comprehensive treatment of urologic and male reproductive system tumors, including robot-assisted and laparoscopic procedures for prostate, bladder, kidney, adrenal, and penile cancers.
Dr. Yang is a Professor, Chief Physician, and Master’s Supervisor, serving as Deputy Director of the First Ward of Urology at Yunnan Cancer Hospital. With 26 years of experience in clinical care, teaching, and research, Dr. Yang completed advanced training at Renji Hospital (Shanghai Jiao Tong University) and the Second Affiliated Hospital of Sun Yat-sen University. Research focuses on urologic and male reproductive tumors.
Professional roles
- Standing Committee Member, Urologic and Male Reproductive System Tumor Professional Committee, Yunnan Anti-Cancer Association
- Standing Committee Member, Urologic Tumor Branch, Yunnan Translational Medicine Society
- Member, Laparoscopy and Robotics Professional Committee, Yunnan Anti-Cancer Association
- Standing Committee Member, Anti-Cancer Drug Professional Committee, Yunnan Anti-Cancer Association
Name order: in Chinese the family name comes first (Yang Hong). Papers usually list the name as Hong Yang or Yang H.
Selected publications
18 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): MRI-derived features reveal recurrence heterogeneity in VI-RADS 2 non-muscle-invasive bladder cancer. PubMed 42755601
- Eur Geriatr Med, 2025 (first author): Sex differences in the association between sarcopenia index and sarcopenia: a cross-sectional study from a Chinese community-based population. PubMed 39623162
- Sci Rep, 2025 (senior author): A lower atherogenic index of plasma was associated with a higher incidence of sarcopenia. PubMed 39825028
- Mol Carcinog, 2024 (first author): circRNA TATA-box binding protein associated factor 15 acts as an oncogene to facilitate bladder cancer progression through targeting miR-502-5p/high mobility group box 3. PubMed 38226841
- BMC Urol, 2022 (senior author): The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. PubMed 36451132
- Ther Adv Med Oncol, 2020 (first author): Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC. PubMed 33240400
- Medicine (Baltimore), 2019 (senior author): Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer. PubMed 31490362
- Oncol Lett, 2017 (first author): Inhibition of Gli1-mediated prostate cancer cell proliferation by inhibiting the mTOR/S6K1 signaling pathway. PubMed 29250185
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion